Advances in controlled drug delivery for treatment of osteoporosis
Osteoporosis is defined as a widespread skeletal condition distinguished by reduced bone strength, low bone mass, altered macro geometry, and micro architectural deterioration of bone tissue. It was first identified from a histological diagnosis but further alterations in mechanical properties was observed due to reductions in both quality and quantity of bone. This condition increases the risk of fractures due to increased porosity & reduced strength. It is the most common bone disease that significantly increases health care costs. Half of osteoporosis patients receive drug treatments, averaging $500 each or $2 billion annually nationwide.